Interferences with cardiac biomarker assays: understanding the clinical impact.

Nevraumont, Arnaud;Deltombe, Matthieu;Favresse, Julien;Guillaume, Louise;Gruson, Damien;et.al.
(2022) European Heart Journal (English Edition) — Vol. 43, n° 24, p. 2286-2288 (2022)

Files

2022_Nevraumont_Eur_Heart_J_Ab.pdf
  • Open Access
  • Adobe PDF
  • 87.36 KB
Download
2022_Nevraumont_Eur_Heart_J.pdf
  • Restricted Access
  • Adobe PDF
  • 464.85 KB
Request a copy

Details

Authors
  • Nevraumont, Arnaudorcid-logoUCLouvain
    Author
  • Deltombe, Matthieuorcid-logoUCLouvain
    Author
  • Favresse, Julien
    Author
  • Guillaume, Louiseorcid-logoUCLouvain
    Author
  • Chapelle, Virginieorcid-logoUCLouvain
    Author
  • Gruson, DamienUCLouvain
    Author
Show more
Abstract
Cardiac biomarkers have a strong value for diagnosis and monitoring of major cardiac diseases with the examples of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) for acute coronary syndrome and B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Nevraumont, A., Deltombe, M., Favresse, J., Guillaume, L., Chapelle, V., Twerenbold, R., & Gruson, D. (2022). Interferences with cardiac biomarker assays: understanding the clinical impact. European Heart Journal (English Edition), 43(24), 2286-2288. https://doi.org/10.1093/eurheartj/ehab924 (Original work published 2022)